267 related articles for article (PubMed ID: 33407852)
1. Micro-RNA-125a mediates the effects of hypomethylating agents in chronic myelomonocytic leukemia.
Berg JL; Perfler B; Hatzl S; Mayer MC; Wurm S; Uhl B; Reinisch A; Klymiuk I; Tierling S; Pregartner G; Bachmaier G; Berghold A; Geissler K; Pichler M; Hoefler G; Strobl H; Wölfler A; Sill H; Zebisch A
Clin Epigenetics; 2021 Jan; 13(1):1. PubMed ID: 33407852
[TBL] [Abstract][Full Text] [Related]
2. Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population-based study.
Zeidan AM; Hu X; Long JB; Wang R; Ma X; Podoltsev NA; Huntington SF; Gore SD; Davidoff AJ
Cancer; 2017 Oct; 123(19):3754-3762. PubMed ID: 28621841
[TBL] [Abstract][Full Text] [Related]
3. Hypomethylating agents in the treatment of chronic myelomonocytic leukemia: a meta-analysis and systematic review.
Xu R; Li M; Wu P; Deng C; Geng S; Huang X; Weng J; Du X
Hematology; 2021 Dec; 26(1):312-320. PubMed ID: 33706667
[TBL] [Abstract][Full Text] [Related]
4. Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents.
Alfonso A; Montalban-Bravo G; Takahashi K; Jabbour EJ; Kadia T; Ravandi F; Cortes J; Estrov Z; Borthakur G; Pemmaraju N; Konopleva M; Bueso-Ramos C; Pierce S; Kantarjian H; Garcia-Manero G
Am J Hematol; 2017 Jul; 92(7):599-606. PubMed ID: 28370097
[TBL] [Abstract][Full Text] [Related]
5. Transcriptomic Signatures of Hypomethylating Agent Failure in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia.
Darbaniyan F; Zheng H; Kanagal-Shamanna R; Lockyer P; Montalban-Bravo G; Estecio M; Lu Y; Soltysiak KA; Chien KS; Yang H; Sasaki K; Class C; Ganan-Gomez I; Do KA; Garcia-Manero G; Wei Y
Exp Hematol; 2022 Nov; 115():44-53. PubMed ID: 36150563
[TBL] [Abstract][Full Text] [Related]
6. Clinical update on hypomethylating agents.
Duchmann M; Itzykson R
Int J Hematol; 2019 Aug; 110(2):161-169. PubMed ID: 31020568
[TBL] [Abstract][Full Text] [Related]
7. Transcription intermediary factor 1γ is a tumor suppressor in mouse and human chronic myelomonocytic leukemia.
Aucagne R; Droin N; Paggetti J; Lagrange B; Largeot A; Hammann A; Bataille A; Martin L; Yan KP; Fenaux P; Losson R; Solary E; Bastie JN; Delva L
J Clin Invest; 2011 Jun; 121(6):2361-70. PubMed ID: 21537084
[TBL] [Abstract][Full Text] [Related]
8. Increasing recognition and emerging therapies argue for dedicated clinical trials in chronic myelomonocytic leukemia.
Renneville A; Patnaik MM; Chan O; Padron E; Solary E
Leukemia; 2021 Oct; 35(10):2739-2751. PubMed ID: 34175902
[TBL] [Abstract][Full Text] [Related]
9. Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia.
Aribi A; Borthakur G; Ravandi F; Shan J; Davisson J; Cortes J; Kantarjian H
Cancer; 2007 Feb; 109(4):713-7. PubMed ID: 17219444
[TBL] [Abstract][Full Text] [Related]
10. Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes.
Brunner AM; Esteve J; Porkka K; Knapper S; Traer E; Scholl S; Garcia-Manero G; Vey N; Wermke M; Janssen JJWM; Narayan R; Fleming S; Loo S; Tovar N; Kontro M; Ottmann OG; Naidu P; Sun H; Han M; White R; Zhang N; Mohammed A; Sabatos-Peyton CA; Steensma DP; Rinne ML; Borate UM; Wei AH
Am J Hematol; 2024 Feb; 99(2):E32-E36. PubMed ID: 37994196
[TBL] [Abstract][Full Text] [Related]
11. MDM2 antagonist improves therapeutic activity of azacitidine in myelodysplastic syndromes and chronic myelomonocytic leukemia.
Wei Y; Zheng H; Lockyer PP; Darbaniyan F; Li Z; Kanagal-Shamanna R; Soltysiak KA; Yang H; Ganan-Gomez I; Montalban-Bravo G; Chien KS; Do KA; Daver N; Garcia-Manero G
Leuk Lymphoma; 2022 Dec; 63(13):3154-3164. PubMed ID: 36059252
[TBL] [Abstract][Full Text] [Related]
12. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial.
Braun T; Itzykson R; Renneville A; de Renzis B; Dreyfus F; Laribi K; Bouabdallah K; Vey N; Toma A; Recher C; Royer B; Joly B; Vekhoff A; Lafon I; Sanhes L; Meurice G; Oréar C; Preudhomme C; Gardin C; Ades L; Fontenay M; Fenaux P; Droin N; Solary E;
Blood; 2011 Oct; 118(14):3824-31. PubMed ID: 21828134
[TBL] [Abstract][Full Text] [Related]
13. Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience.
Pepe S; Scalzulli E; Colafigli G; Di Prima A; Diverio D; Mancini M; Latagliata R; Martelli M; Foà R; Breccia M
Ann Hematol; 2020 Oct; 99(10):2405-2416. PubMed ID: 32813071
[TBL] [Abstract][Full Text] [Related]
14. Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.
Harel S; Cherait A; Berthon C; Willekens C; Park S; Rigal M; Brechignac S; Thépot S; Quesnel B; Gardin C; Adès L; Fenaux P; Braun T
Leuk Res; 2015 May; 39(5):501-4. PubMed ID: 25735917
[TBL] [Abstract][Full Text] [Related]
15. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.
Kantarjian H; Oki Y; Garcia-Manero G; Huang X; O'Brien S; Cortes J; Faderl S; Bueso-Ramos C; Ravandi F; Estrov Z; Ferrajoli A; Wierda W; Shan J; Davis J; Giles F; Saba HI; Issa JP
Blood; 2007 Jan; 109(1):52-7. PubMed ID: 16882708
[TBL] [Abstract][Full Text] [Related]
16. A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia.
Bazinet A; Darbaniyan F; Kadia TM; Venugopal S; Kanagal-Shamanna R; DiNardo CD; Borthakur G; Jabbour EJ; Daver NG; Pemmaraju N; Konopleva MY; Ravandi F; Sasaki K; Chien KS; Hammond D; Pierce SA; Kantarjian HM; Garcia-Manero G; Montalban-Bravo G
Cancer; 2023 Feb; 129(4):560-568. PubMed ID: 36458426
[TBL] [Abstract][Full Text] [Related]
17. [Clinical Efficacy of Hypomethylating Agent Therapy in Patients with Chronic Myelomonocytic Leukemia].
Li X; Wang Y; Guo YJ; Niu ZY; Ma L; Zhou XQ; Zhang JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):257-261. PubMed ID: 38387931
[TBL] [Abstract][Full Text] [Related]
18. Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia.
Helbig G; Chromik K; Woźniczka K; Kopińska AJ; Boral K; Dworaczek M; Koclęga A; Armatys A; Panz-Klapuch M; Markiewicz M
Pathol Oncol Res; 2019 Jul; 25(3):1175-1180. PubMed ID: 30613922
[TBL] [Abstract][Full Text] [Related]
19. Activity of azacitidine in chronic myelomonocytic leukemia.
Costa R; Abdulhaq H; Haq B; Shadduck RK; Latsko J; Zenati M; Atem FD; Rossetti JM; Sahovic EA; Lister J
Cancer; 2011 Jun; 117(12):2690-6. PubMed ID: 21656746
[TBL] [Abstract][Full Text] [Related]
20. Decitabine demonstrates antileukemic activity in B cell precursor acute lymphoblastic leukemia with MLL rearrangements.
Roolf C; Richter A; Konkolefski C; Knuebel G; Sekora A; Krohn S; Stenzel J; Krause BJ; Vollmar B; Murua Escobar H; Junghanss C
J Hematol Oncol; 2018 May; 11(1):62. PubMed ID: 29728108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]